Nureca Board Approves Q4 FY26 Results, Appoints New CFO, Reappoints Directors, Approves Capex
Nureca Limited approved its audited Q4 FY26 standalone and consolidated financial results. The company appointed Mr. Chander Kant as CFO and approved reappointments of Mr. Aryan Goyal (Whole Time Director & CEO) and Mr. Saurabh Goyal (Managing Director). An incremental capex of up to ₹100 crore was approved for manufacturing facilities.
The outcome of the board meeting includes financial results, significant management changes (CFO appointment, director reappointments), and a substantial capital expenditure plan, all of which have a high impact on the company's operations and future prospects.
The company reported its financial results and made several key appointments and reappointments, including a new CFO and reconfirmations of directorial roles. The approval of significant capex also indicates a positive outlook for future growth.
Nureca Limited announced the outcome of its Board Meeting held on May 29, 2026. The Board approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026, with an unmodified opinion from the Statutory Auditors.
The company also approved the appointment of M/s MGSG and Associates as Internal Auditors for the Financial Year 2026-27. Mr. Chander Kant has been appointed as the new Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective June 27, 2026, following the resignation of Mr. Naresh Gupta, whose last day will be June 26, 2026.
Key leadership reappointments were also approved, subject to shareholder approval at the forthcoming Annual General Meeting (AGM). Mr. Aryan Goyal was reappointed as Whole Time Director & Chief Executive Officer for three years effective May 28, 2027. Mr. Saurabh Goyal was reappointed as Managing Director for three years effective September 03, 2026. Ms. Smita Goyal was appointed as Additional Director (Whole Time Director) for three years effective June 01, 2026. Additionally, Mr. Aryan Goyal, who retires by rotation, was approved for re-appointment at the ensuing 10th AGM.
The Board approved an incremental capex of up to ₹100 crore for plant and machinery for manufacturing additional medical devices, healthcare consumables, and hygiene products at their existing industrial land in Sundran, Punjab. They also approved the purchase of additional land adjoining their industrial land for future expansion.
The 10th AGM is scheduled for Tuesday, July 28, 2026, conducted via video conferencing. The Register of Members and Share Transfer Books will be closed from July 22, 2026, to July 28, 2026, inclusive, for the AGM. The Board Meeting commenced at 3:00 PM and concluded at 4:57 PM.
What to do with a filing like this
Nureca Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nureca Limited. Read the original for the full detail.